Patents by Inventor Mitsuko Ideno

Mitsuko Ideno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180362933
    Abstract: The present invention produces a large number of mesenchymal stem cells in a short time in a medium containing no heterologous components by including a step for culturing a cell population containing mesenchymal stem cells in the presence of a fibronectin fragment.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 20, 2018
    Applicant: TAKARA BIO INC.
    Inventors: Kenichi TAHARA, Ikuei NUKAYA, Mitsuko IDENO, Saori YAMAGUCHI, Junichi MINENO
  • Patent number: 9062287
    Abstract: A process for producing a cell mass containing natural killer cells, characterized by involving a step of carrying out the expansion culture of a cell mass containing natural killer cells and/or cells capable of being differentiated into natural killer cells in the presence of a biological response modifier and cells that has been so treated as to lose a proliferation capability, and others.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: June 23, 2015
    Assignee: TAKARA BIO INC.
    Inventors: Mitsuko Ideno, Mie Yabuuchi, Meiko Jin, Masae Sato, Naoko Ashida, Tatsuji Enoki
  • Patent number: 8975070
    Abstract: The present invention relates to a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one of induction, maintenance and expansion of a cytotoxic lymphocyte in the presence of fibronectin, a fragment thereof or a mixture thereof.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: March 10, 2015
    Assignee: Takara Bio Inc.
    Inventors: Hiroaki Sagawa, Mitsuko Ideno, Ikunoshin Kato
  • Patent number: 8927273
    Abstract: The present invention provides a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one step selected from induction, maintenance and expansion of a cytotoxic lymphocyte using a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 5% by volume, in the presence of fibronectin, a fragment thereof or a mixture thereof.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: January 6, 2015
    Assignee: Takara Bio Inc.
    Inventors: Mitsuko Ideno, Nobuko Muraki, Kinuko Ogawa, Masayuki Kishimoto, Tatsuji Enoki, Hiroaki Sagawa, Ikunoshin Kato
  • Publication number: 20140212972
    Abstract: The present invention relates to a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one of induction, maintenance and expansion of a cytotoxic lymphocyte in the presence of fibronectin, a fragment thereof or a mixture thereof.
    Type: Application
    Filed: April 10, 2014
    Publication date: July 31, 2014
    Applicant: TAKARA BIO INC.
    Inventors: Hiroaki SAGAWA, Mitsuko IDENO, lkunoshin KATO
  • Patent number: 8728811
    Abstract: The present invention relates to a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one of induction, maintenance and expansion of a cytotoxic lymphocyte in the presence of fibronectin, a fragment thereof or a mixture thereof.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: May 20, 2014
    Assignee: Takara Bio Inc.
    Inventors: Hiroaki Sagawa, Mitsuko Ideno, Ikunoshin Kato
  • Patent number: 8216837
    Abstract: A method of producing lymphocytes characterized by comprising the step of culturing lymphocytes in the presence of a modified recombinant fibronectin fragment which has overlapping parts of the heparin-binding domain of fibronectin. This method makes it possible to achieve a high cell proliferation rate. The lymphocytes obtained thereby are appropriately usable in, for example, adoptive immunotherapy and, therefore, expected as highly useful in the clinical field. Moreover, a novel modified recombinant fibronectin fragment is provided.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: July 10, 2012
    Assignee: Takara Bio Inc.
    Inventors: Nobuko Muraki, Mitsuko Ideno, Kinuko Nagamine, Fuyuko Takashima, Eiji Kobayashi, Akiko Kato, Takahiro Marui, Hiroaki Sagawa, Tatsuji Enoki, Ikunoshin Kato
  • Publication number: 20120171173
    Abstract: A process for producing a cell mass containing natural killer cells, characterized by involving a step of carrying out the expansion culture of a cell mass containing natural killer cells and/or cells capable of being differentiated into natural killer cells in the presence of a biological response modifier and cells that has been so treated as to lose a proliferation capability, and others.
    Type: Application
    Filed: September 10, 2010
    Publication date: July 5, 2012
    Inventors: Mitsuko Ideno, Mie Yabuuchi, Meiko Jin, Masae Sato, Naoko Ashida, Tatsuji Enoki
  • Publication number: 20110158954
    Abstract: A method for preparing a ?? T cell population, characterized in that the method includes the step of culturing a cell population containing ?? T cells, in the presence of (a) fibronectin, a fibronectin fragment or a mixture thereof and (b) an activating factor of ?? T cells. According to the present invention, a method for preparing a ?? T cell population is provided. The ?? T cell population obtained by the method is suitably used in, for example, immunotherapy. Therefore, the method of the present invention is expected to greatly contribute to a medical field.
    Type: Application
    Filed: March 4, 2008
    Publication date: June 30, 2011
    Inventors: Mitsuko Ideno, Fumiyo Sakai, Tatsuji Enoki, Ikunoshin Kato
  • Patent number: 7910368
    Abstract: The present invention is a method for inducing cytotoxic T cell having an antigen-specific cytotoxic activity, a method for maintaining the cell, a method for continuously culturing the cell or a method for expanding the cell, comprising the step of culturing a cytotoxic T cell in the presence of at least one substance selected from the group consisting of (A) a substance having a binding activity to CD44; (B) a substance capable of regulating a signal emitted by binding a CD44 ligand to CD44; (C) a substance capable of inhibiting binding of a growth factor to a growth factor receptor; (D) a substance capable of regulating a signal emitted by binding of a growth factor to a growth factor receptor; and (E) fibronectin, a fragment thereof or a mixture thereof.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: March 22, 2011
    Assignee: Takara Bio Inc.
    Inventors: Hiroaki Sagawa, Mitsuko Ideno, Ikunoshin Kato
  • Patent number: 7816134
    Abstract: The present invention provides methods for inducing, maintaining and expanding CTL (cytotoxic T cell) having an antigen-specific cytotoxic activity at a high level, which is useful in the adoptive immunotherapy, by using as an effective ingredient at least one compound selected from the group consisting of acidic polysaccharides, acidic oligosaccharides, acidic monosaccharides, and salts thereof. The above-mentioned compounds include fucoidans, heparins, alginic acid, chondroitin sulfate A, chondroitin sulfate B, pectic acid, hyaluronic acid, degradation products of fucoidans, sulfated glucose, sulfated fucose and salts thereof.
    Type: Grant
    Filed: August 15, 2001
    Date of Patent: October 19, 2010
    Assignee: Takara Bio Inc.
    Inventors: Hiroaki Sagawa, Mitsuko Ideno, Ikunoshin Kato
  • Publication number: 20100255578
    Abstract: A method of producing lymphocytes characterized by comprising the step of culturing lymphocytes in the presence of a modified recombinant fibronectin fragment which has overlapping parts of the heparin-binding domain of fibronectin. This method makes it possible to achieve a high cell proliferation rate. The lymphocytes obtained thereby are appropriately usable in, for example, adoptive immunotherapy and, therefore, expected as highly useful in the clinical field. Moreover, a novel modified recombinant fibronectin fragment is provided.
    Type: Application
    Filed: June 7, 2007
    Publication date: October 7, 2010
    Inventors: Nobuko Muraki, Mitsuko Ideno, Kinuko Nagamine, Fuyuko Takashima, Eiji Kobayashi, Akiko Kato, Takahiro Marui, Hiroaki Sagawa, Tatsuji Enoki, Ikunoshin Kato
  • Publication number: 20100247579
    Abstract: The present invention relates to a method for treatment of cancer, which comprises the following steps (A) and (B): (A) applying a treatment which induces the reduction in lymphocytes to a patient; and (B), subsequent to step (A), administering lymphocytes to the patient promptly. The present invention also relates to a cancer therapeutic agent and a cancer treatment kit for use in the method. When the method is used as an immunoreconstructive therapy, the decrease in immunologic competence which may be caused by the reduction in lymphocytes can be avoided and, therefore, the risk of the occurrence of an infectious disease can be decreased.
    Type: Application
    Filed: May 8, 2008
    Publication date: September 30, 2010
    Inventors: Hiroshi Shiku, Shinichi Kageyama, Shigehisa Kitano, Mitsuko Ideno, Keisuke Tomita, Tatsuji Enoki, Kazutoh Takesako, Ikunoshin Kato
  • Publication number: 20100068192
    Abstract: A method for preparing a T cell population, wherein the T cell population expresses CD45RA and expresses at least one selected from the group consisting of CD62L, CCR7, CD27, and CD28, characterized in that the method comprises the step of culturing a cell population comprising a T cell, in the presence of fibronectin, a fragment thereof or a mixture thereof.
    Type: Application
    Filed: September 27, 2006
    Publication date: March 18, 2010
    Applicant: TAKARA BIO INC.
    Inventors: Tatsuji Enoki, Akiko Kato, Mitsuko Ideno, Hiroaki Sagawa, Ikunoshin Kato
  • Publication number: 20090221077
    Abstract: The present invention provides a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one step selected from induction, maintenance and expansion of a cytotoxic lymphocyte using a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 5% by volume, in the presence of fibronectin, a fragment thereof or a mixture thereof.
    Type: Application
    Filed: August 19, 2004
    Publication date: September 3, 2009
    Inventors: Mitsuko Ideno, Nobuko Muraki, Kinuko Ogawa, Masayuki Kishimoto, Tatsuji Enoki, Hiroaki Sagawa, Ikunoshin Kato
  • Publication number: 20080227204
    Abstract: The present invention relates to a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one of induction, maintenance and expansion of a cytotoxic lymphocyte in the presence of fibronectin, a fragment thereof or a mixture thereof.
    Type: Application
    Filed: July 31, 2007
    Publication date: September 18, 2008
    Applicant: TAKARA BIO INC.
    Inventors: Hiroaki Sagawa, Mitsuko Ideno, Ikunoshin Kato
  • Publication number: 20080166325
    Abstract: The present invention provides methods for inducing, maintaining and expanding CTL (cytotoxic T cell) having an antigen-specific cytotoxic activity at a high level, which is useful in the adoptive immunotherapy, by using as an effective ingredient at least one compound selected from the group consisting of acidic polysaccharides, acidic oligosaccharides, acidic monosaccharides, and salts thereof. The above-mentioned compounds include fucoidans, heparins, alginic acid, chondroitin sulfate A, chondroitin sulfate B, pectic acid, hyaluronic acid, degradation products of fucoidans, sulfated glucose, sulfated fucose and salts thereof.
    Type: Application
    Filed: April 23, 2007
    Publication date: July 10, 2008
    Inventors: Hiroaki Sagawa, Mitsuko Ideno, Ikunoshin Kato
  • Publication number: 20050227354
    Abstract: The present invention relates to a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one of induction, maintenance and expansion of a cytotoxic lymphocyte in the presence of fibronectin, a fragment thereof or a mixture thereof.
    Type: Application
    Filed: March 25, 2003
    Publication date: October 13, 2005
    Inventors: Hiroaki Sagawa, Mitsuko Ideno, Ikunoshin Kato
  • Publication number: 20050042208
    Abstract: The present invention is a method for inducing cytotoxic T cell having an antigen-specific cytotoxic activity, a method for maintaining the cell, a method for continuously culturing the cell or a method for expanding the cell, comprising the step of culturing a cytotoxic T cell in the presence of at least one substance selected from the group consisting of (A) a substance having a binding activity to CD44; (B) a substance capable of regulating a signal emitted by binding a CD44 ligand to CD44; (C) a substance capable of inhibiting binding of a growth factor to a growth factor receptor; (D) a substance capable of regulating a signal emitted by binding of a growth factor to a growth factor receptor; and (E) fibronectin, a fragment thereof or a mixture thereof.
    Type: Application
    Filed: August 15, 2002
    Publication date: February 24, 2005
    Inventors: Hiroaki Sagawa, Mitsuko Ideno, Ikunoshin Kato
  • Publication number: 20040115809
    Abstract: The present invention provides methods for inducing, maintaining and expanding CTL (cytotoxic T cell) having an antigen-specific cytotoxic activity at a high level, which is useful in the adoptive immunotherapy, by using as an effective ingredient at least one compound selected from the group consisting of acidic polysaccharides, acidic oligosaccharides, acidic monosaccharides, and salts thereof. The above-mentioned compounds include fucoidans, heparins, alginic acid, chondroitin sulfate A, chondroitin sulfate B, pectic acid, hyaluronic acid, degradation products of fucoidans, sulfated glucose, sulfated fucose and salts thereof.
    Type: Application
    Filed: February 12, 2003
    Publication date: June 17, 2004
    Inventors: Hiroaki Sagawa, Mitsuko Ideno, Ikunoshin Kato